Ligand Pharmaceuticals Incorporated (LGND) Social Stream
Ligand Pharmaceuticals Inc (LGND) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Ligand Pharmaceuticals Inc.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
LGND's average price target has moved down $19.54 over the prior 44 weeks.
Over the past 47 weeks, LGND's average upside potential has been 64.57%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
LGND Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 26 weeks, LGND's average broker recommendation rating improved by 1.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- To contextualize these metrics, consider that out of all US stocks, Ligand Pharmaceuticals Inc's average analyst price target is greater than 446.1% of them.
- In the context of all US stocks, Ligand Pharmaceuticals Inc's variance in analysts' estimates is lower than -300.6% of them.
- In terms of how Ligand Pharmaceuticals Inc fares relative to stocks in the mid market cap category, note that its upside potential (average analyst target price relative to current price) is higher than 376.44% of that group.
- Ligand Pharmaceuticals Inc's number of analysts covering the stock is greater than 128.7% of stocks in the mid market cap category.
In the Pharmaceutical Products industry, LEGN, LCI, and LBPS are the three stocks most similar to Ligand Pharmaceuticals Inc regarding the price target and analyst recommendation information presented here.
Make investment decisions regarding LGND using the data that counts. Try POWR Ratings for free.